TipRanks
Advertisement
Advertisement

DE:ITH0 Stock Latest News

Nektar’s rezpegaldesleukin featured in published atopic dermatitis trial
The FlyNektar’s rezpegaldesleukin featured in published atopic dermatitis trial
21d ago
NKTR
Nektar reinstated with a Neutral at JPMorgan
PremiumThe Fly
Nektar reinstated with a Neutral at JPMorgan
25d ago
NKTR
Nektar Therapeutics’ Earnings Call Highlights Rezpeg Momentum
PremiumCompany Announcements
Nektar Therapeutics’ Earnings Call Highlights Rezpeg Momentum
26d ago
NKTR
Nash Reiterates Buy on Nektar, Citing Strong Cash Position and Rezpegaldesleukin Progress; Keeps $153 Price Target Unchanged
PremiumRatings
Nash Reiterates Buy on Nektar, Citing Strong Cash Position and Rezpegaldesleukin Progress; Keeps $153 Price Target Unchanged
29d ago
NKTR
Nektar: Strong Cash Runway and Rezpeg Momentum Support Unchanged $185 Price Target and Buy Rating
PremiumRatings
Nektar: Strong Cash Runway and Rezpeg Momentum Support Unchanged $185 Price Target and Buy Rating
29d ago
NKTR
Nektar Therapeutics Initiated at Buy on Rezpeg’s Advancing Pivotal Programs and Solid Cash Runway
PremiumRatingsNektar Therapeutics Initiated at Buy on Rezpeg’s Advancing Pivotal Programs and Solid Cash Runway
29d ago
NKTR
Nektar reports Q2 EPS ($1.23), consensus ($2.04)
Premium
The Fly
Nektar reports Q2 EPS ($1.23), consensus ($2.04)
1M ago
NKTR
Nektar: Rezpeg’s Advancing Phase 3 Programs and Disease‑Modifying Potential Support Buy/High Risk Rating with Price Target Maintained at $151
Premium
Ratings
Nektar: Rezpeg’s Advancing Phase 3 Programs and Disease‑Modifying Potential Support Buy/High Risk Rating with Price Target Maintained at $151
1M ago
NKTR
NKTR Earnings this Week: How Will it Perform?
PremiumPre-Earnings
NKTR Earnings this Week: How Will it Perform?
1M ago
NKTR
Nektar initiated with a Buy at Canaccord on rezpegaldesleukin potential
PremiumThe Fly
Nektar initiated with a Buy at Canaccord on rezpegaldesleukin potential
2M ago
NKTR
Nektar initiated with a Buy at Canaccord
PremiumThe Fly
Nektar initiated with a Buy at Canaccord
2M ago
NKTR
Nektar begins Phase 3 program of rezpegaldesleukin in atopic dermatitis
PremiumThe Fly
Nektar begins Phase 3 program of rezpegaldesleukin in atopic dermatitis
2M ago
NKTR
Canaccord sees potential Apogee buyout as ‘huge win’ for sector
PremiumThe FlyCanaccord sees potential Apogee buyout as ‘huge win’ for sector
3M ago
ABBV
APGE
Nektar Stockholders Approve Governance and Incentive Plan Changes
Premium
Company Announcements
Nektar Stockholders Approve Governance and Incentive Plan Changes
3M ago
8K
NKTR
Nektar management to meet with Piper Sandler
Premium
The Fly
Nektar management to meet with Piper Sandler
4M ago
NKTR
Nektar price target lowered to $80 from $95 at Wedbush
PremiumThe Fly
Nektar price target lowered to $80 from $95 at Wedbush
4M ago
NKTR
Nektar Therapeutics Charts Aggressive Path With REZPEG
PremiumCompany Announcements
Nektar Therapeutics Charts Aggressive Path With REZPEG
4M ago
NKTR
Nektar Therapeutics Establishes New Equity Distribution Agreement
PremiumCompany Announcements
Nektar Therapeutics Establishes New Equity Distribution Agreement
4M ago
8K
NKTR
Julian Harrison Reiterates Buy on Nektar, Citing Robust REZPEG Program and Strong Balance Sheet; Maintains $178 Price Target
PremiumRatings
Julian Harrison Reiterates Buy on Nektar, Citing Robust REZPEG Program and Strong Balance Sheet; Maintains $178 Price Target
4M ago
NKTR
Nektar price target raised to $192 from $105 at Piper Sandler
PremiumThe FlyNektar price target raised to $192 from $105 at Piper Sandler
4M ago
NKTR
Nektar Therapeutics: Strong Cash Position and Late‑Stage Autoimmune Pipeline Underpin Attractive Risk‑Reward and Outperform Rating
Premium
Ratings
Nektar Therapeutics: Strong Cash Position and Late‑Stage Autoimmune Pipeline Underpin Attractive Risk‑Reward and Outperform Rating
4M ago
NKTR
Nektar reports Q1 adjusted EPS ($1.82), consensus ($1.48)
Premium
The Fly
Nektar reports Q1 adjusted EPS ($1.82), consensus ($1.48)
4M ago
NKTR

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >